张琪阅读次数:15437添加时间:2009-4-28姓名：张琪职称：教授，硕士生导师学术兼职：江苏省高校医药教育研究会副理事长；江苏省药理学会常务理事；《中国临床药理学与治疗学》、《中华男科学杂志》编委教育简历：中国药科大学药理学博士；美国纽约州立大学布法罗分校（StateUniversityofNewYorkatBuffalo）博士后。研究领域：药理学、药物动力学、代谢组学。在基础研究领域着重于各类新药的临床前与临床的药物动力学、药效学筛选、药理学机制靶点、药效-药动学模型研究，以及骨质疏松症、高脂血症等重大疾病的代谢组学研究。尤其是代谢组学方法学及其应用的研究成果处于国内外前列。主持了碱性成纤维细胞生长因子、黄芪甲苷、磷酸二果糖锶等一类新药的药理学、药动学研究及Etanercept、银杏提取物、硝苯地平缓释片、阿斯匹林缓释片等四十多种新药的药理学、药物动力学、生物等效性研究及相关的新药报批，推动企业新药成果的市场转化。近年来负责国家自然科学基金三项（主持两项：“二磷酸果糖锶防治男性性功能低下：对雄性素生成等相关基因的调控”、“二磷酸果糖锶盐对抗ET-ROS介导的雄性性功能低下与睾丸退行性病变”；联合单位负责人一项“miR-30a介导炎症信号的异常转归影响精子成熟的机制研究”）；国际合作项目一项（PK/PD/PG/DISModelsforEtanerceptInteractionswithCytokinesinaRatModelofRA）；省基金一项（抗骨质疏松一类新药的临床前研究）；参与国家、省部科研项目8项；主持企业合作项目40多项。申请专利3项（2项授权）。发表学术文章61篇（30篇被SCI收录）；参与编写英文论著一部、中文著作多部。所获荣誉：江苏省“333高层次人才培养工程”培养对象江苏省“六大人才高峰”培养对象南京市“321”领军型科技创业人才南京工业大学首届“工大才俊”高层次人才培养对象讲授课程：药理学、药物动力学（本科生课程）；现代药理学（研究生课程）科研成果：参与编写的中英文论著：英文论著：《Strontium:ChemicalProperties,ApplicationsandHealthEffects》一书中的第一章节“TheEffectsofStrontiumonPhysiology,PharmacologyandToxicityoftheHuman”出版社：NOVAPublishers出版日期：2013年ISBN：978-1-62257-631-9中文论著：《10000个科学难题（医学卷）》，“药动学-药效学结合模型—连接体内药物浓度与药效关系的桥梁”，科学出版社，2011年8月正式出版，P955-958。“十一五”国家重点图书出版规划项目近年发表的SCI文章：[1]MetabolomicProfilesDelineateSignatureMetabolicShiftsduringEstrogenDeficiency-InducedBoneLossinRatbyGC-TOF/MS.PLOSONE,2013,8(2):e54965.[2]SimultaneousdeterminationofEleutherosideBandEleutherosideEinratplasmabyhighperformanceliquidchromatography-electrosprayionizationmassspectrometryanditsapplicationinapharmacokineticstudy.JChromatogrBAnalytTechnolBiomedLifeSci,2013,917-918:84-92.[3]Rapidanalysisoftadalafilinhumanbloodplasmaandseminalplasmabyliquidchromatography/tandemmassspectrometry.JPharmBiomedAnal,2013,77C:149-157.[4]SimultaneousDeterminationofOridonin,PonicidinandRosmarinicAcidfromHerbaIsodiRubescentisExtractbyLC-MS-MSinRatPlasma.JChromatogrSci,2013.[5]Developmentandvalidationofasensitiveliquidchromatography/tandemmassspectrometrymethodforthedeterminationofraddeaninAinratplasmaanditsapplicationtoapharmacokineticstudy.JChromatogrBAnalytTechnolBiomedLifeSci,2013,912:16-23.[6]Strontiumfructose1,6-fiphosphate(FDP-Sr)treatmentpreventsbonelossinaratmodelofpostmenopausalosteoporosisviaOPG\RANKL\RANKpathway.ActaPharmacologicaSinica,2012,33(4):479-489IF:1.95[7]Simultaneousdeterminationoforidonin,ponicidinandrosmarinicacidfromHerbaIsodiRubescentisextractbyLC-MS/MSinratplasma.JournalofChromatographicScience2012[8]Developmentandvalidationofasensitiveliquidchromatography/tandemmassspectrometrymethodforthedeterminationofraddeaninAinratplasmaanditsapplicationtoapharmacokineticstudy.JournalofChromatographyB，2013（912）:16-23[9]ComparisonofsildenafilwithstrontiumfructosediphosphateinimprovingerectiledysfunctionagainstupregulatedcavernosalNADPHoxidase,proteinkinaseCε,andendothelinsystemindiabeticrats.JPharmPharmacol.2012Feb;64(2):244-51.[10]GC-TOF/MS-basedmetabolomicproilingofestrogendeiciency-inducedobesityinovariectomizedrats.ActaPharmacologicaSinica2011(32):270-278[11]Synthesisandpharmacokineticsofstrontiumfructose1,6-diphosphate(Sr-FDP)asapotentialanti-osteoporosisagentinintactandovariectomizedrats.JInorgBiochem,2011,105(4):563-568.[12]DeterminationofstrontiuminratplasmaandplasmaultrafiltratebyZeemanFurnaceatomicabsorptionspectroscopyanditsapplicationtoapharmacokineticstudy.AfricanJournalofBiotechnology2011.10(78),18039-18045[13]Pharmacokinetic—Pharmacodynamic—DiseaseProgressionModelforEffectofEtanerceptinLewisRatswithCollagen-InducedArthritis,PharmRes.2011（28）:1622-1630[14]SildenafilandFDP-SrattenuatediabeticcardiomyopathybysuppressingabnormalexpressionofmyocardialCASQ2,FKBP12.6,andSERCA2ainrats.ActaPharmacologicaSinica,2011,32:441-448.I[15]SildenafilimprovesdiabeticvascularactivitythroughsuppressingendothelinreceptorA,iNOSandNADPHoxidasewhichiscomparablewiththeendothelinreceptorantagonistCPU0213inSTZ-injectedrats.JournalofPharmacyandPharmacology,2011,63:943-951.[16]Metabonomicprofilingofdiet-inducedhyperlipidaemiainaratmodel.Biomarkers2010May;15(3):205-16.[17]UpregulatedNADPHOxidaseContributestoDiabeticTesticularComplicationandisRelievedbyStrontiumFructose1,6-Diphosphate.ExpClinEndocrinolDiabetes2010;118:459–465.[18]Strontiumfructose1,6-diphosphatealleviatesearlydiabetictestopathybysuppressingabnormaltesticularmatrixmetallop-roteinasesysteminstreptozocin-treatedrats[J].JPharmacyPharmacology,2009,61:229-236[19](2-Pyridyl)acetone-PromotedCu-CatalyzedO-ArylationofPhenolswithArylIodides,Bromides,andChlorides.TheJournalofOrganicChemistry,2009,74:7187–7190[20]ApplicationofGC/MS-basedmetabonomicprofilinginstudyingthelipid-regulatingeffectsofGinkgobilobaextractondiet-inducedhyperlipidemiainrats.ActaPharmacologicaSinica,2009,30(12):1674-1687[21]Effectsofstrontiumfructose1,6-diphosphateonexpressionofapoptosis-relatedgenesandoxidativestressintestesofdiabeticrats[J].InternationalJournalofUrology(2008)15,251–256[22]AnewchromoneglycosidefromRhododendronspinuliferum.ArchivesofPharmacalResearch(2008),31(8),970-972.[23]GC/MSanalysisoftheraturineformetabonomicresearch[J].JournalofChromatographyB2007,854(2),20-25.[24]PharmacokineticsofastragalosideⅣinbeagledogs[J].EuropeanJournalofDrugMetabolismandPharmacokinetics2007,32(2),75-9.[25]StrontiumFructose1,6-diphosphateRescuesadenine-inducedMaleHypogonadismandUpregulatestheTesticularEndothelin-1System[J].ClinicalandExperimentalPharmacologyandPhysiology2007,34:1131-1137.[26]PharmacokineticsofAstragalosideIVinRatsbyliquidhromatographycoupledwithtandemmasspectrometry[J].EuropeanJournalofDrugMetabolismandPharmacokinetics2005,30(4),269-273.[27]PharmacokineticsofRecombinantHumanBasicFibroblastGrowthFactorinMiceusingaRadioiodionati-onmethodcombinedwithSDS-PAGEandaSandwichEnzyme-LinkedImmunosorbentAssay[J].EuropeanJournalofDrugMetabolismandPharmacokinetics2004,29(3),163-168[28].Pharmacokineticsofrecombinanthumanbasicfibroblastgrowthfactorinrabbitsandmiceserumandrabbitsaqueoushumor[J].ActaPharmacolSin,2004Aug;25(8):991-995.本文共分1页